Resistance to p53-mediated growth suppression in human ovarian cancer cells retain endogenous wild-type p53

Anticancer Research

Volumn 22, Issue 2 A, 2002, Pages 659-664

  Jin, X ^a   Burke, W ^a   Rothman, K ^a   Lin, J ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Apoptosis; Growth suppression; Ovarian cancer; p53; Trans activation

Indexed keywords

CASPASE 9; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME DEGRADATION; GENE INDUCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ADENOVIRIDAE; APOPTOSIS; BCL-X PROTEIN; CASPASES; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036254630     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
2. p53 is required for radiation-induced apoptosis in mouse thymocytes
3. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest
4. A p53-dependent mouse spindle checkpoint
5. WAFI, a potential mediator of p53 tumor suppression
6. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
7. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
8. The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles and a "gain of function" phenotype
9. Amplification of a gene encoding a p53-associated protein in human sarcomas
10. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene
11. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein
12. The MDM2 gene amplification database
13. Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion
14. Wild-type p 53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors
15. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer
16. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma
17. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
18. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines
19. Bcl-XL protects cancer cells from p53-mediated apoptosis
20. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
21. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta
22. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53
23. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein
24. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
25. Cooperative DNA binding of p53 with TFIID (TBP): A possible mechanism for transcriptional activation
26. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription
27. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
28. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells
29. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemo-resistant human ovarian cancer cells